R&D

R&DPerforms strongly. Pipeline consists of 27 projects for medicines and vaccines for priority pathogens. Its two clinical-stage medicines are both novel. Reports access and/or stewardship planning for most of its late-stage projects and leads in intellectual capital sharing.

Performs strongly. Pipeline consists of 27 projects for medicines and vaccines for priority pathogens, including two novel projects. Reports access and/or stewardship planning for most of its late-stage projects and leads in intellectual capital sharing.

Performs strongly. Reports comprehensive environmental risk-management strategy for own sites and suppliers; risk assessments based on discharge limits have been completed at own sites and are ongoing at suppliers’ sites.

Performs strongly. Files its on- and off-patent products for registration in access countries. Leader in strategies for continuous supply to access countries.

Performs well. It has educational programmes with comprehensive COI mitigation. Regressed from 2018 to now to only partially decoupling sales incentives from volumes. It shares surveillance results and adapts brochures and packaging for appropriate use.